# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

> **NCT02517359** · PHASE1 · TERMINATED · sponsor: **Respivert Ltd** · enrollment: 55 (actual)

## Conditions studied

- Asthma
- Healthy Volunteers

## Interventions

- **DRUG:** RV6153 single dose
- **DRUG:** RV6153 matching placebo single dose
- **DRUG:** RV6153 14 day repeat dose
- **DRUG:** RV6153 matching placebo 14 day repeat dose
- **DRUG:** RV6153 28 day repeat dose
- **DRUG:** RV6153 matching placebo 28 day repeat dose

## Key facts

- **NCT ID:** NCT02517359
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Preset pharmacokinetic stopping criteria met at lower doses than expected.
- **Last updated:** 2016-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517359, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02517359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*